Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001631-46
    Sponsor's Protocol Code Number:NL65876.078.18
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-02-13
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2018-001631-46
    A.3Full title of the trial
    Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease
    Implementatie van farmacokinetisch gestuurd doseren van DDAVP en VWF-bevattende stollingsfactorconcentraten bij von Willebrandziekte
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effects of pharmacokinetic models in dosing of DDAVP and/or von Willebrand factor-containing concentrates in patients with von Willebrand disease
    Effecten van farmacokinetische modellen bij het doseren van DDAVP en/of von Willebrand factor-bevattende concentraten in patiënten met von Willebrandziekte
    A.3.2Name or abbreviated title of the trial where available
    OPTI-CLOT: To WiN
    A.4.1Sponsor's protocol code numberNL65876.078.18
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorErasmus University Medical Center
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportErasmus University Medical center
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationErasmus University Medical Center
    B.5.2Functional name of contact pointW. Al Arashi
    B.5.3 Address:
    B.5.3.1Street AddressWytemaweg 80
    B.5.3.2Town/ cityRotterdam
    B.5.3.3Post code3015 CN
    B.5.3.4CountryNetherlands
    B.5.6E-mailw.alarashi@erasmusmc.nl
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Minrin
    D.2.1.1.2Name of the Marketing Authorisation holderFerring BV
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESMOPRESSIN
    D.3.9.1CAS number 16679-58-6
    D.3.9.4EV Substance CodeSUB07001MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Octostim
    D.2.1.1.2Name of the Marketing Authorisation holderFerring BV
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESMOPRESSIN
    D.3.9.1CAS number 16679-58-6
    D.3.9.4EV Substance CodeSUB07001MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Octostim
    D.2.1.1.2Name of the Marketing Authorisation holderFerring BV
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Nasal spray
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPNasal use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESMOPRESSIN
    D.3.9.1CAS number 16679-58-6
    D.3.9.4EV Substance CodeSUB07001MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Haemate P
    D.2.1.1.2Name of the Marketing Authorisation holderCSL Behring Gmbh
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN VON WILLEBRAND FACTOR
    D.3.9.3Other descriptive nameHUMAN VON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB22288
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN COAGULATION FACTOR VIII
    D.3.9.3Other descriptive nameHUMAN COAGULATION FACTOR VIII
    D.3.9.4EV Substance CodeSUB13813MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Wilate
    D.2.1.1.2Name of the Marketing Authorisation holderOctapharma Gmbh
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN COAGULATION FACTOR VIII
    D.3.9.3Other descriptive nameHUMAN COAGULATION FACTOR VIII
    D.3.9.4EV Substance CodeSUB13813MIG
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN VON WILLEBRAND FACTOR
    D.3.9.3Other descriptive nameHUMAN VON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB22288
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Wilfactin
    D.2.1.1.2Name of the Marketing Authorisation holderLFB Biomedicaments
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN VON WILLEBRAND FACTOR
    D.3.9.3Other descriptive nameHUMAN VON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB22288
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Veyvondi
    D.2.1.1.2Name of the Marketing Authorisation holderBaxalta Innovations GmbH
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder and solvent for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVON WILLEBRAND FACTOR
    D.3.9.1CAS number 109319-16-6
    D.3.9.3Other descriptive nameVON WILLEBRAND FACTOR
    D.3.9.4EV Substance CodeSUB72116
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Von Willebrand disease
    Von Willebrandziekte
    E.1.1.1Medical condition in easily understood language
    Von Willebrand disease
    Von Willebrandziekte
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10055168
    E.1.2Term Von Willebrand's factor deficiency
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To investigate the reliability and feasibility of PK-guided dosing of DDAVP and/or VWF-containing concentrate in VWD patients.

    Onderzoeken of het doseren op basis van populatie PK-modellen in VWD-patiënten betrouwbaar en uitvoerbaar is.

    E.2.2Secondary objectives of the trial
    Not applicable
    Niet van toepassing
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - VWD and low VWF patient of all ages, with all types of VWD and “low VWF”;
    - Undergoing a DDAVP-test, and/or
    - Undergoing a medical intervention requiring treatment with DDAVP and/or VWF-containing concentrates with monitoring of FVIII and VWF levels. Medical interventions may include: dental, surgical or diagnostic procedures, and child deliveries in the hospital setting as examples. , or
    - With bleeding requiring treatment with DDAVP and/or VWF-containing concentrate with monitoring of FVIII and VWF levels, or
    - Requiring a PK profile for future medical intervention or bleeding episode, or
    - With prescribed or requiring prophylaxis with VWF-containing concentrate due to bleeding frequency.
    - Geen minimum or maximum leeftijd op inclusiedatum;
    - Hemorrhagische diathese of een familieanamnese van von Willebrandziekte met historisch laagste waarden van VWF:Ag <0.30 IU/ml en/of VWF:Act <0.30 IU/ml (<0.50 IU/ml in patiënten die alleen een DDAVP-test ondergaan) en/of FVIII <0.40 IU/ml;
    - Indicatie voor een DDAVP-test; en/of
    - Indicatie voor eenmedische interventie waarvoor behandeling met DDAVP en/of stollingsfactorconcentraat benodigd. Medische interventie is zoals operaties, tandheelkundige ingrepen of (geplande) bevallingen in het ziekenhuis; or
    - Bloeding waarvoor behandeling met DDAVP en/of stollingsfactorconcentraat benodigd is;
    - Schriftelijke toestemming (informed consent) van patiënt (en indien patiënt <16 jaar, toestemming van ouders)
    E.4Principal exclusion criteria
    - Any other known hemostatic abnormalities;
    - Acquired VWD;
    - Presence of VWF antibodies (>0.2 BU)
    - Withdrawal of (parental) informed consent.
    - Enige andere stollingsafwijking
    - Verworven VWD
    - Aanwezigheid van VWF antistoffen (>0.2 BU)
    - Intrekking van (ouderlijke) toestemming
    E.5 End points
    E.5.1Primary end point(s)
    A. In case of DDAVP-testing: predictive performance of the DDAVP population PK model: reliability of predicted FVIII and VWF:Act levels (U/ml), defined as difference between predicted and actual FVIII and VWF:Act levels (U/ml).
    B. In case of elective medical interventions and treatment with DDAVP or VWF-containing concentrate: predictive performance of the Bayesian adaptive approach using the population PK model for either DDAVP or VWF-containing concentrate: reliability of predicted FVIII and VWF:Act levels (U/ml), defined as difference between predicted and actual FVIII and VWF:Act levels (U/ml) achieved after dosing according to target levels stated by consensus and treating physician.
    C. In case of treatment of a bleeding episode with DDAVP or VWF-containing concentrate: predictive performance of the respective population PK models: reliability of predicted FVIII and VWF:Act levels (U/ml), defined as difference between predicted and actual FVIII and VWF:Act levels (U/ml) achieved after dosing.
    D. In case of prophylaxis with VWF-containing concentrate: reliability of predicted FVIII and VWF:Act levels, defined as difference between predicted and actual FVIII and VWF:Act levels achieved after dosing (predictive performance).
    A. In geval van DDAVP-test: voorspellende prestatie van het DDAVP populatie PK-model: betrouwbaarheid van voorspelde FVIII- en VWF:Act spiegels (U/ml), gedefinieerd als het verschil tussen de voorspelde en werkelijke FVIII- en VWF:Act spiegels (U/ml).
    B. In geval van electieve medische interventie en behandeling met DDAVP of VWF-bevattend concentraat: voorspellende prestatie van de Bayesiaanse aanpassingsmethode, gebruik makend van het populatie PK-model voor DDAVP dan wel VWF-bevattend concentraat: betrouwbaarheid van voorspelde FVIII- en VWF:Act spiegels (U/ml), gedefinieerd als het verschil tussen de voorspelde en werkelijke FVIII- en VWF:Act spiegels (U/ml), bereikt na doseren o.b.v. de door de richtlijn en behandeld arts gestelde streefwaarden.
    C. In geval van een bloeding en behandeling met DDAVP of VWF-bevattend concentraat: voorspellende prestatie van de respectievelijke populatie PK-modellen: betrouwbaarheid van voorspelde FVIII- en VWF:Act spiegels (U/ml), gedefinieerd als het verschil tussen de voorspelde en werkelijke FVIII- en VWFAct spiegels (U/ml), bereikt na doseren.
    D. In geval van profylaxe met VWF-bevatten concentraat: voorspellende prestatie van de Bayesiaanse aanpassingsmethode, gebruik makend van het populatie PK-model voor VWF-bevattend concentraat:.betrouwbaarheid van voorspelde FVIII- en VWF:Act spiegels (U/ml), gedefinieerd als het verschil tussen de voorspelde en werkelijke FVIII- en VWF:Act spiegels (U/ml), bereikt na doseren o.b.v. de door de richtlijn en behandeld arts gestelde streefwaarden.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1.
    A. At least at time points t = 0 h, 1 h and 3 or 4 h after administration of DDAVP, possibly also at t = 6 h and 24 h.
    B. Daily from first dose up to 14 days after surgery.
    C. Daily from first or second dose up to 14 days after start of bleeding.
    D. Three days for the PK-profile. During the follow up 6 times over a period of 36 months
    1.
    A. Minstens op tijdspunten t = 0 h, 1 h en 3 of 4 h na toediening van DDAVP, mogelijk ook op t = 6 en 24 h.
    B. Dagelijks vanaf de eerste dosis t/m 14 dagen na de ingreep.
    C. Dagelijks vanaf de eerste of tweede dosis t/m 14 dagen na start van de bloeding.
    D. Drie dagen voor het PK-profiel. Tijdens de follow-up 6 keer over een periode van 36 maanden.
    E.5.2Secondary end point(s)
    1. (Only in B & C): number and timing of DDAVP administrations and/or timing and dosing (U/kg) of VWF-containing concentrate infusions.
    2. (Only in B & C): hemostasis as quantified by hemoglobin values (mmol/l), amount of blood loss (ml), incidence of thrombosis, and need for blood transfusion and/or (re)-operation.
    3. (Only in B & C): duration of hospitalization (days), clinical visit (days).
    4. (Only in B & C): feasibility of intervention with regard to patient and physician satisfaction and economic impact.
    5. (Only in case of DDAVP-testing or DDAVP-treatment): DDAVP plasma concentrations (pg/ml).
    6. (only in D): Association of (real life or simulated) FVIII and VWF:act (trough and peak levels) with bleeding episodes.
    1. (Alleen in B & C): aantal en timing van DDAVP-toedieningen en/of timing en dosering (U/kg) van VWF-bevattend concentraat infusies.
    2. (Alleen in B & C): hemostase, gekwantificeerd aan de hand van hemoglobinewaarden (mmol/l), hoeveelheid bloedverlies (ml), incidentie van trombose, en benodigde bloedtransfusies en/of (re)operaties.
    3. (Alleen in B & C): duur van ziekenhuisopname (dagen), ziekenhuisbezoeken (dagen).
    4. (Alleen in B & C): uitvoerbaarheid van de interventie, gemeten aan de hand van tevredenheid van patiënt en behandelaar en economische impact.
    6. (Alleen in geval van DDAVP-test of DDAVP-behandeling): DDAVP plasmaconcentraties (pg/ml).
    7. (Alleen in D): De associatie van (real life of voorspelde) FVIII en VWF: Act (top- en dalspeigels) met bloedingsepisodes.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1.
    A. At least at time points t = 0 h, 1 h and 3 or 4 h after administration of DDAVP, possibly also at t = 6 h and 24 h.
    B. Daily from first dose up to 14 days after surgery.
    C. Daily from first or second dose up to 14 days after start of bleeding.
    2, 3, 4. From first dose up to 14 days after surgery, or from first or second dose up to 14 days after start of bleeding.
    5. At the end of treatment, or 14 days after surgery or start of bleeding.
    6.
    A. At least at time points t = 0 h, 1 h and 3 or 4 h after administration of DDAVP, possibly also at t = 6 h and 24 h.
    B & C. Daily from first dose up to 14 days after surgery, or from first or second dose up to 14 days after start of bleeding.
    D. Three days for the PK-profile. During the follow up 6 times over a period of 36 months.
    A. Minstens op tijdspunten t = 0 h, 1 h en 3 of 4 h na toediening van DDAVP, mogelijk ook op t = 6 en 24 h.
    B. Dagelijks vanaf 1ste dosis t/m 14 dagen na de ingreep.
    C. Dagelijks vanaf 1ste of 2de dosis t/m 14 dagen na start van de bloeding.
    2, 3, 4. Vanaf de eerste dosis t/m 14 dagen na de ingreep, of vanaf de eerste of tweede dosis t/m 14 dagen na bloeding.
    5. Aan het eind van de behandeling, of 14 dagen na de ingreep of start van de bloeding.
    A. Minstens op tijdspunten t = 0 h, 1 h en 3 of 4 h na toediening van DDAVP, mogelijk ook op t = 6 en 24 h.
    B &C. Dagelijks vanaf de eerste dosis t/m 14 dagen na de ingreep, of vanaf de eerste of tweede dosis t/m 14 dagen na start bloeding.
    D. Drie dagen voor het PK-profiel. Tijdens de follow-up 6 keer over een periode van 36 maanden.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 30
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 15
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 15
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 110
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2019-02-13. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women Yes
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    From children <12 years, parental informed consent will be obtained.
    Bij kinderen <12 jaar zal ouderlijke toestemming worden gevraagd.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state160
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment will be resumed.
    De normale behandeling zal worden hervat.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-02-13
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-02-14
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:09:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA